State-level, out-of-pocket insulin caps do not substantially increase utilization, study finds

Adults with type 1 diabetes (T1D) have an elevated risk for cardiovascular disease (CVD) compared with the general population. HbA1c is the primary modifiable risk factor for CVD in T1D. Fewer than 1% of patients achieve euglycemia (<5.7% HbA1c). Ketogenic…

Researchers at Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type 2 diabetes (T2D).…

Daily insulin injections can be burdensome to patients but are the cornerstone of type 1 diabetes management and often become necessary over time for type 2 diabetes. Could they soon become a thing of the past, asks Jacqui Wise

The effectiveness of a new…

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.1 Findings were published today in The Lancet Diabetes…

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

July 14 (UPI) -- Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says.

GLP-1 agonists could be given to millions with heart conditions to help them stay out of hospital and live longer

Continuous Glucose Monitors Help Type 2 Diabetes Patients Spend Five More Hours a Day in Healthy Blood Sugar Range